Radiotherapy of Multiple Brain Metastases Using AGuIX®
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a Prospective Randomized Open Blinded Endpoint phase II clinical trial. The study
will be adaptive: an interim analysis is planned after enrolment of 20 patients in each arm
of treatment (WBRT and AGuIX® + WBRT), to select and continue the study with group(s) that
present the best response rate to the experimental treatment (AGuIX® + WBRT).
The main endpoint will be evaluated by a blinded endpoint committee.